Ambulatory Care Self-Assessment Program (ACSAP) 2026 (L269025)
ACPE Numbers: Various – see listing below Release Date: March 16, 2026 Expiration Dates: March 16, 2027 Activity Type: Application-based CE Credits: 16 contact hours (BPS and ACPE) Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 8 learning modules (see table below) and provides up to 16 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCACP recertification approved by the BPS.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
Board certified pharmacists are eligible to receive up to 16 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCACP.
Learning Activity
Passing Score
Credit Information
Resistant Hypertension
73%
1.5 Contact Hours
BPS: BCACP ACPE: 0217-9999-26-037-H01-P
Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Classify the importance of accurate blood pressure measurement, medication adherence, and lifestyle modifications that impact blood pressure.
Evaluate secondary causes of resistant hypertension (RHTN).
Assess the drug therapy options for treatment of RHTN.
Analyze the newly approved and in-pipeline pharmacologic treatment options for RHTN.
Assess the different procedural interventions approved or in-pipeline for managing RHTN.
Develop a pharmacologic treatment plan for a patient with RHTN based on the latest guideline recommendations.
Chapter: Heart Failure with Mildly Reduced or Preserved Ejection Fraction ACPE #: 0217-9999-26-032-H01-P
Assess drug therapies for heart failure (HF) with ejection fraction (EF) greater than 40%.
Distinguish the differences in the drug therapy recommendations from the latest and leading guidelines for HF with EF greater than 40%, and distinguish from recommendations for HF with reduced EF.
Develop a pharmacologic treatment plan for HF with EF greater than 40% that optimizes the use of guideline-directed medical therapy.
Develop an outpatient diuretic and fluid management plan for HF.
Resolve practical issues in the pharmacologic management of HF.
Case Series: Cardiovascular Risk Stratification ACPE #: 0217-9999-26-031-H01-P
Evaluate the clinical use of cardiovascular risk stratification methods to guide preventive and therapeutic recommendations.
Assess cardiovascular risk to determine actionable risk modification strategies.
Design patient-specific care plans that include nonpharmacologic therapies to reduce cardiovascular risk.
Justify cardiovascular risk modification strategies in patients with comorbid chronic disease states such as type 2 diabetes, hypertension, dyslipidemia, and tobacco use disorder.
Assess the differences between attention-deficit/hyperactivity disorder (ADHD) between adult and pediatric presentations.
Analyze the available treatment guidelines for adult and pediatric ADHD.
Distinguish the difference between newer pharmacologic options and older agents.
Evaluate current evidence-based literature comparing ADHD medications to establish an appropriate treatment plan.
Devise a treatment plan for ADHD accounting for adverse effects and monitoring.
Chapter: Pediatric Substance Use ACPE #: 0217-9999-26-036-H01-P
Evaluate the screening, brief intervention, referral to treatment (SBIRT) model for youth with substance use disorders (SUDs).
Distinguish between hallmark features of cannabis use disorder, nicotine use disorder, alcohol use disorder, opioid use disorder, and stimulant use disorder.
Analyze the role of medication treatment for SUD.
Develop a monitoring plan and appropriate treatment/supportive care recommendations for withdrawal symptoms.
Evaluate the role of harm reduction strategies to support pediatric patients.
Chapter: Management of Frail Patients ACPE #: 0217-9999-26-034-H01-P
Estimate frailty through evaluation of patient risk factors and available screening tools.
Evaluate a patient’s medication regimen for appropriate and potentially inappropriate medications.
Design a tailored plan considering nonpharmacologic and pharmacologic interventions for a frail patient with hypertension, diabetes, or insomnia.
Analyze fall, fracture, or bleeding risk for a frail patient to implement appropriate risk mitigation strategies.
Chapter: Management of Overweight and Obesity ACPE #: 0217-9999-26-035-H01-P
Distinguish the differences in treatments for the management of overweight and obesity.
Assess and design a pharmacotherapy plan for a patient with overweight or obesity given patient-specific factors.
Devise monitoring values to determine the efficacy and safety of anti-obesity pharmacotherapy.
Evaluate available literature to bridge gaps in knowledge with emerging evidence.
Chapter: Integrating Pharmacogenomics into Primary Care ACPE #: 0217-9999-26-033-H01-P
Discover resources for interpreting and applying pharmacogenomic results to prescribing decisions.
Assess the impact of a pharmacogenomic result on a medication outcome.
Design a pharmacogenomic-informed care-plan for personalized treatment.
Evaluate strategies and best practices for integrating pharmacogenomic results into primary care workflows.
Detect ethical, legal, and social considerations for integrating pharmacogenomics in primary care.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Stock Ownership: Michelle Fine (Eli Lilly; AbbVie; Amgen;AstraZeneca: BeiGeneLtd; Bristor Myers Squibb;Chugai Pharmaceutical;Daiichi Sankyo; GileadSciences; Johnson &Johnson; Novo Nordisk;Pfizer; Zoetis;Procter &Gamble; Stryker)
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
Complete the attestation statement
Review all content
Complete and pass the assessments
Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
